Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 4 (April)

1. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.
   BMC Cancer, 6: 63. [Abstract] [Full-text]
2. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
   Br J Cancer, 94(7): 1016-20. [Abstract] [Full-text]
3. Role of exon-16-deleted HER2 in breast carcinomas.
   Endocr Relat Cancer, 13(1): 221-32. [Abstract] [Full-text]
4. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
   Endocr Relat Cancer, 13(1): 39-49. [Abstract] [Full-text]
5. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members.
   Cancer Gene Ther, 13(5): 490-502. [Abstract] [Full-text]
6. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
   Clin Cancer Res, 12(7): 2255-63. [Abstract] [Full-text]
7. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
   Oncologist, 11(4): 318-24. [Abstract] [Full-text]
8. Second-line treatment of postmenopausal women with advanced breast carcinoma.
   Expert Rev Anticancer Ther, 6(4): 613-24. [Abstract] [Full-text]
9. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
   J Clin Oncol, 24(12): 1831-8. [Abstract] [Full-text]
10. HER2 expression as a potential marker for response to therapy targeted to the EGFR.
    Br J Cancer, 94(8): 1144-53. [Abstract] [Full-text]
11. In vitro cytotoxicity of (211)At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
    Nucl Med Biol, 33(3): 333-47. [Abstract] [Full-text]
12. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
    Cancer Treat Rev, 32(3): 180-90. [Abstract] [Full-text]
13. Monoclonal and bispecific antibodies as novel therapeutics.
    Arch Immunol Ther Exp (Warsz). [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.